{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:24:01Z","timestamp":1791901441207,"version":"4.3.4"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012547","name":"Natural Science Foundation of Guangxi Zhuang Autonomous Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012547","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p>The morphological variability and genetic complexity of fibroblastic sarcoma makes its diagnosis and treatment a challenge. High-mobility group box 1 protein (HMGB1), which functions as a DNA chaperone and a prototypical damage-associated molecular pattern, plays a paradoxical role in cancer. However, the expression pattern and role of HMGB1 in fibroblastic sarcomas is ill defined. By immunostaining of 95 tissue microarray cores of fibroblastic sarcomas, HMGB1 was found to be expressed in most tumor tissues. Nuclear HMGB1 translocation to cytoplasm was observed both in tumor cells and vascular endothelial cells. A visible number of tumor-associated myeloid cells including CD68<jats:sup>+<\/jats:sup> and CD163<jats:sup>+<\/jats:sup> macrophages and CD33<jats:sup>+<\/jats:sup> myeloid cells were also detected in most tumor tissues. HMGB1 translocation was not only associated with CD68, CD163, and CD33 density, but also with disease progression. These results imply that HMGB1, an important regulator of the tumor microenvironment, is associated with tumor-associated myeloid cells and involved in the progression of fibroblastic sarcomas; HMGB1 may serve as a promising prognostic biomarker and a potential therapeutic target for fibroblastic sarcoma.<\/jats:p>","DOI":"10.3389\/pore.2021.608582","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T04:11:56Z","timestamp":1617163916000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["HMGB1 Translocation is Associated with Tumor-Associated Myeloid Cells and Involved in the Progression of Fibroblastic Sarcoma"],"prefix":"10.3389","volume":"27","author":[{"given":"Huoying","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxue","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"key":"B1","volume-title":"Soft tissue sarcoma statistics","author":"Cancer Research UK","year":"2013"},{"key":"B2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2350\/10-12-0944-PB.1","article-title":"Fibroblastic and myofibroblastic tumors in children and adolescents","volume":"15","author":"Coffin","year":"2012","journal-title":"Pediatr Dev Pathol"},{"key":"B3","volume-title":"World Health Organization classification of tumours of soft tissue and bone","author":"Fletcher","year":"2013"},{"key":"B4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11864-019-0606-9","article-title":"First-line therapy for metastatic soft tissue sarcoma","volume":"20","author":"Meyer","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/COC.0b013e318209cd72","article-title":"Risk factors for local recurrence and metastasis in soft tissue sarcomas of the extremity","volume":"35","author":"Sabolch","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1001\/jamaoncol.2015.3101","article-title":"First-line aldoxorubicin vs doxorubicin in metastatic or locally advanced unresectable soft-tissue sarcoma","volume":"1","author":"Chawla","year":"2015","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10637-016-0333-z","article-title":"Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation","volume":"34","author":"Gupta","year":"2016","journal-title":"Invest New Drugs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"The Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1158\/1078-0432.CCR-15-0491","article-title":"Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors","volume":"22","author":"Merchant","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.coi.2008.04.012","article-title":"HMGB1: a two-headed signal regulating tumor progression and immunity","volume":"20","author":"Campana","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1158\/1078-0432.CCR-13-0495","article-title":"HMGB1 in cancer: good, bad, or both?","volume":"19","author":"Kang","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.imbio.2016.06.009","article-title":"Toll-like receptor stimulation in cancer: a pro- and anti-tumor double-edged sword","volume":"222","author":"Dajon","year":"2017","journal-title":"Immunobiology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1146\/annurev.immunol.021908.132603","article-title":"HMGB1 and RAGE in inflammation and cancer","volume":"28","author":"Sims","year":"2010","journal-title":"Annu Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/ni.2376","article-title":"Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.pupt.2017.05.015","article-title":"HMGB1 promotes HLF-1 proliferation and ECM production through activating HIF1-\u03b1-regulated aerobic glycolysis","volume":"45","author":"Xu","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/eji.201444908","article-title":"HMGB1 induces angiogenesis in rheumatoid arthritis via HIF-1\u03b1 activation","volume":"45","author":"Park","year":"2015","journal-title":"Eur J Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1016\/j.bbadis.2017.07.012","article-title":"Non-oxidizable HMGB1 induces cardiac fibroblasts migration via CXCR4 in a CXCL12-independent manner and worsens tissue remodeling after myocardial infarction","volume":"1863","author":"Di Maggio","year":"2017","journal-title":"Biochim Biophys Acta (Bba) Mol Basis Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/cas.12133","article-title":"Low molecular weight heparin suppresses receptor for advanced glycation end products-mediated expression of malignant phenotype in human fibrosarcoma cells","volume":"104","author":"Takeuchi","year":"2013","journal-title":"Cancer Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-030-30845-2_3","article-title":"Tumor-associated myeloid cells in cancer progression","volume-title":"Cancer immunology","author":"Gulic","year":"2020"},{"key":"B22","doi-asserted-by":"publisher","first-page":"39888","DOI":"10.1074\/jbc.M110.128348","article-title":"High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity","volume":"285","author":"Evankovich","year":"2010","journal-title":"J Biol Chem"},{"key":"B23","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/35012626","article-title":"Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases","volume":"405","author":"Taguchi","year":"2000","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/leu.2010.225","article-title":"HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells","volume":"25","author":"Liu","year":"2011","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1189\/jlb.0908578","article-title":"Ethyl pyruvate administration inhibits hepatic tumor growth","volume":"86","author":"Liang","year":"2009","journal-title":"J Leukoc Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"5299","DOI":"10.1038\/onc.2010.261","article-title":"HMGB1 release and redox regulates autophagy and apoptosis in cancer cells","volume":"29","author":"Tang","year":"2010","journal-title":"Oncogene"},{"key":"B28","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/21460","article-title":"Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins","volume":"399","author":"Ohndorf","year":"1999","journal-title":"Nature"},{"key":"B29","first-page":"422","article-title":"High mobility group box 1 (HMGB1) expression in gastric adenocarcinomas","volume":"23","author":"Suren","year":"2018","journal-title":"J BUON"},{"key":"B30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3892\/or.2012.2070","article-title":"Expression and clinical significance of HMGB1 in human liver cancer: knockdown inhibits tumor growth and metastasis in vitro and in vivo","volume":"29","author":"Dong","year":"2013","journal-title":"Oncol Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/pin.12393","article-title":"Cytoplasmic expression of high mobility group B1 (HMGB1) is associated with tumor-infiltrating lymphocytes (TILs) in breast cancer","volume":"66","author":"Lee","year":"2016","journal-title":"Pathol Int"},{"key":"B32","doi-asserted-by":"publisher","first-page":"960","DOI":"10.22037\/uj.v10i3.1425","article-title":"Cytosolic HMGB1 expression in human renal clear cell cancer indicates higher pathological T classifications and tumor grades","volume":"10","author":"Takeuchi","year":"2013","journal-title":"Urol J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00428-015-1861-1","article-title":"High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers","volume":"467","author":"Lee","year":"2015","journal-title":"Virchows Arch"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3390\/cancers6031670","article-title":"Tumor-associated macrophages as major players in the tumor microenvironment","volume":"6","author":"Chanmee","year":"2014","journal-title":"Cancers"},{"key":"B35","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.addr.2015.11.009","article-title":"Tumor-associated macrophages: potential therapeutic targets for anti-cancer therapy","volume":"99","author":"Komohara","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"B36","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.oraloncology.2019.04.019","article-title":"Prognostic significance of CD68+ and CD163+ tumor associated macrophages in head and neck squamous cell carcinoma: a systematic review and meta-analysis","volume":"93","author":"Troiano","year":"2019","journal-title":"Oral Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.2217\/fon-2018-0669","article-title":"Prognostic impact of tumor-associated macrophage infiltration in esophageal cancer: a meta-analysis","volume":"15","author":"Li","year":"2019","journal-title":"Future Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1747340","DOI":"10.1080\/2162402X.2020.1747340","article-title":"Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas","volume":"9","author":"Dancsok","year":"2020","journal-title":"Oncoimmunology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4049\/jimmunol.1701019","article-title":"Myeloid-derived suppressor cells: immune-suppressive cells that impair antitumor immunity and are sculpted by their environment","volume":"200","author":"Ostrand-Rosenberg","year":"2018","journal-title":"J.I."},{"key":"B40","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.coi.2018.03.009","article-title":"Plasticity of myeloid-derived suppressor cells in cancer","volume":"51","author":"Tcyganov","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B41","first-page":"449","article-title":"Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer","volume":"27","author":"Akaike","year":"2007","journal-title":"Anticancer Res"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2021.608582\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T14:43:03Z","timestamp":1626187383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2021.608582\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":41,"alternative-id":["10.3389\/pore.2021.608582"],"URL":"https:\/\/doi.org\/10.3389\/pore.2021.608582","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,31]]},"article-number":"608582"}}